SHENZHEN, China & ROCKVILLE, Md .– (BUSINESS WIRE) – HighTide Therapeutics (“HighTide”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for non-viral chronic liver disease, gastrointestinal disorders and metabolic disorders, announced today that the company has managed a Conduct company presentation will attend one-on-one meetings for investors at the BofA Securities 2021 Health Care Conference from May 10th to 13th, 2021.
HighTide will be presented on Thursday, May 13, 2021 at 8:00 a.m. EDT.
About HighTide Therapeutics
HighTide Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutics for non-viral chronic liver disease, gastrointestinal disorders, and metabolic disorders. The focus is on areas of high unmet medical need and lack of effective treatment options.
About HTD1801
HighTide’s lead product candidate, HTD1801, an ionic salt of berberine and ursodeoxycholic acid, is a premier drug and new molecular entity developed to treat primary sclerosing cholangitis (PSC), alcohol-free steatohepatitis (NASH), and primary biliary cholangitis (PBC) . HTD1801 has been named Fast Track for PSC and NASH and Orphan Drug for PSC by the US FDA. Further information can be found at https://hightidetx.com/.
